EARLY CLOSE OF OFFERING OF SHARES IN ORPHAZYME

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This announcement does not constitute an offering circular and nothing herein contains an offering of securities. No one should purchase or subscribe for any securities in Orphazyme A/S ("Orphazyme" or the "Company") except on the basis of information in the offering circular published by the Company in connection with the offering and admission of such securities to trading and official listing on Nasdaq Copenhagen A/S ("Nasdaq Copenhagen"). Copies of the offering circular are available at the Company's registered office and, subject to certain exceptions, through the website of the Company.

Early close of offering of shares in Orphazyme

With reference to the company announcement no. 2/2017 dated 6 November 2017 and the offering circular dated 6 November 2017 published in connection with the initial public offering and admission of its shares to trading and official listing on Nasdaq Copenhagen (the "Offering"), Orphazyme today announces early close of the Offering.

Orphazyme has decided that the Offering to retail investors in Denmark for individual orders up to and including DKK 3 million each will be closed at 00:01 (CET) on 15 November 2017. The Offering to institutional investors will close at 11:00 (CET) on 15 November 2017.

The early close of the Offering to retail and institutional investors is due to the aggregate demand exceeding the expected allocation of offer shares.

Information about result of the Offering, including the offer price and allocation of shares, is expected to be announced on 16 November 2017 allowing first day of trading and official listing on Nasdaq Copenhagen to be on 16 November 2017 under the symbol "ORPHA TEMP".

Bank syndicate

Carnegie and Danske Bank are acting as Joint Global Coordinators and Joint Bookrunners, and Oddo BHF SCA is acting as Co-Lead Manager for the proposed IPO.

For additional information, please contact

Orphazyme

 

Anders Hinsby, CEO

+45 31 44 31 39

Impact Partners

 

Michael Steen-Knudsen +45 25 17 18 15